How would you approach a patient with metastatic colon cancer and BRCA2 mutation in next generation sequencing?
Would you consider using PARP Inhibitor in this situation?
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Mayo Clinic
Answered on
We detect more mutations as more patients get next generation sequencing during their colorectal cancer treatment. The BRCA mutation is one of them.
BRCA mutations are typically associated with breast, ovarian, pancreas, and prostate cancers. The relationship between BRCA mutations and colorectal can...
Join for free or sign in to see the full answer